American Journal of Medicine and Medical Sciences
p-ISSN: 2165-901X e-ISSN: 2165-9036
2019; 9(2): 63-70
doi:10.5923/j.ajmms.20190902.06
S. V. Kamishov , M. N. Tillyashaykhov
Republican Specialized Scientific-Practical Medical Center of Oncology and Radiology of Ministry of Health of the Republic of Uzbekistan
Copyright © 2019 The Author(s). Published by Scientific & Academic Publishing.
This work is licensed under the Creative Commons Attribution International License (CC BY).
http://creativecommons.org/licenses/by/4.0/
When prescribing extracorporeal immunopharmacotherapy methods for patients with cervical and ovarian cancers, the results of clinical and diagnostic studies, anamnestic data, the presence of specific antitumor or alternative treatments before admission to the hospital, as well as the histological type of the tumor, the macroscopic form of growth and the degree of its prevalence were taken into account. Extracorporeal immunopharmacotherapy methods are recognized, first of all, to reduce toxic manifestations after chemotherapy and radiation therapy as well as to improve the general condition after extensive surgery in patients with oncologic diseases. In the course of the conducted surveys an algorithm for preparing patients with cervical and ovarian cancers to perform EIFT techniques was developed and it included: 1) the study of anamnestic data (the presence of concomitant diseases and earlier symptomatic or specific treatment); 2) the study of general clinical and biochemical analysis of blood; 3) the study of immunological parameters; 4) study of urinalysis; 5) study of the degree of toxicity of chemotherapy by the CTC-NCIC scale; 6) study of the subjective general condition of patients (Performancestatus) by the Karnovsky’s scale and ECOG (WHO); 7) assessment of the quality of patients life according to the SF-36 questionnaire; 8) the conclusion of the cardiologist; 9) if necessary, conservative fortifying, cardiotropic, hepatotropic and other types of therapy were given to patients.
Keywords: Ovarian cancer, Cervical cancer, Immunotherapy, Extracorporeal immunopharmacotherapy, Polychemotherapy
Cite this paper: S. V. Kamishov , M. N. Tillyashaykhov , Extracorporal Immunopharmacotherapy in Complex Treatment of Cervical Cancer and Ovarian Cancer, American Journal of Medicine and Medical Sciences, Vol. 9 No. 2, 2019, pp. 63-70. doi: 10.5923/j.ajmms.20190902.06.
Figure 2. Comparative assessment of the total cumulative five-year survival according to KaplanE.L. et Meier R. in patients with OC depending on the type of immunotherapy in complex treatment |
Figure 3. Progression risk ratio (hazardratio, HR) and risk of death in patients with cervical cancer |
Figure 4. Progression risk ratio (hazardratio, HR) and risk of death in patients with ovarian cancer |